Fintel reports that on April 7, 2025, HC Wainwright & Co. initiated coverage of Ionis Pharmaceuticals (NasdaqGS:IONS) with a ...

Research analysts at HC Wainwright increased their Q1 2025 earnings per share (EPS) estimates for Surrozen in a report issued on Wednesday, April 2nd. HC Wainwright analyst M. Caufield now anticipates ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $2.79, a high ...

Equities researchers at HC Wainwright lowered their FY2025 EPS estimates for Draganfly in a report issued on Thursday, April 3rd. HC Wainwright analyst S. Buck now anticipates that the company will ...

HC Wainwright initiates Ionis with Buy rating and $45 target, citing strong pipeline, solid revenue, and key clinical ...

Regulatory News: MaaT Pharma (EURONEXT: MAAT – the "Company"), a clinical-stage biotechnology company and a leader in the ...

Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

Vanda's strong financials and product lineup show promise, but management concerns and FDA disputes may hinder growth. Learn ...

Highlights,Cabaletta Bio receives a favorable evaluation from HC Wainwright.,An institutional review brings renewed focus to ...

Rezolve AI Limited (NASDAQ:RZLV) is known for offering AI-driven solutions that focus on improving the digital shopping ...

H.C. Wainwright sees increased uncertainty for Sarepta’s Elevidys franchise after the European Medicines Agency placed a clinical hold on three drug trials. The clinical hold on ...